Clinical Trial Market Research Reports & Industry Analysis
Clinical Trial Industry Research & Market Reports
-
Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
... - Drugs In Development, 2022'; Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) pipeline Target constitutes close to 38 molecules. Out of which approximately 30 molecules are developed by companies and remaining by the universities/institutes. Histone ... Read More
-
Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
... Summary Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) pipeline Target constitutes close to 32 molecules. Out of which approximately 28 molecules are developed by companies ... Read More
-
Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
... Players, 2022 Update Summary Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) pipeline Target constitutes close to 19 molecules. Out of which approximately ... Read More
-
Chronic Obstructive Pulmonary Disease (COPD) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... (COPD) - Drugs In Development, 2022, provides an overview of the Chronic Obstructive Pulmonary Disease (COPD) (Respiratory) pipeline landscape. Chronic obstructive pulmonary disease (COPD) is a group of lung diseases. It is characterized by inability ... Read More
-
Bone Metastasis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... provides an overview of the Bone Metastasis (Oncology) pipeline landscape. Bone metastasis occurs when cancer cells spread from their original site to a bone. Signs and symptoms of bone metastasis include bone pain, broken bones, ... Read More
-
Retinoblastoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... overview of the Retinoblastoma (Oncology) pipeline landscape. Retinoblastoma is an eye cancer that begins in the retina. Symptoms include white color in the center circle of the eye (pupil), eye redness, vision problems, a different ... Read More
-
Ureter Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... provides an overview of the Ureter Cancer (Oncology) pipeline landscape. Ureter cancer or ureteral cancer is cancer of the ureter. Symptoms and signs of urethral cancer include bleeding from the urethra or blood in the ... Read More
-
Optic Neuritis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... provides an overview of the Optic Neuritis (Ophthalmology) pipeline landscape. Optic neuritis is an inflammation of the optic nerve, the bundle of nerve fibers that transmits visual information from eye to brain. Symptoms include pain, ... Read More
-
Pompe Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... provides an overview of the Pompe Disease (Metabolic Disorders) pipeline landscape. Pompe disease is an inherited disorder caused by defect in a gene called GAA. The GAA gene is responsible for the production of the ... Read More
-
Post Menopausal Osteoporosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... Development, 2022, provides an overview of the Post Menopausal Osteoporosis (Metabolic Disorders) pipeline landscape. Postmenopausal osteoporosis is the most common form of osteoporosis. It affects many women after menopause. Symptoms include back pain, loss of ... Read More
-
Russia AI-based Clinical Trials Solution Provider Market: Prospects, Trends Analysis, Market Size and Forecasts up to 2028
... study of the Russia market. Moreover, the report provides deep insights into demand forecasts, market trends, and, micro and macro indicators in the Russia market. Also, factors that are driving and restraining the AI-based clinical ... Read More
-
Hairy Cell Leukemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... Development, 2022, provides an overview of the Hairy Cell Leukemia (Oncology) pipeline landscape. Hairy cell leukemia is a rare, slow-growing cancer of the blood in which bone marrow makes too many B cells (lymphocytes), a ... Read More
-
Keratitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... overview of the Keratitis (Ophthalmology) pipeline landscape. Keratitis is an inflammation of the cornea. Symptoms include eye redness, eye pain, blurred vision, decreased vision and sensitivity to light. Risk factors include virus infections, injury, climatic ... Read More
-
Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
... Growth Factor Related Protein or PGF) - Placental growth factor is a protein encoded by the PGF gene. Placental growth factor (PGF) is a member of the VEGF (vascular endothelial growth factor). It plays an ... Read More
-
Behcet Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... provides an overview of the Behcet Disease (Cardiovascular) pipeline landscape. Behcet disease (BEH-chets), sometimes called Behcet syndrome, Morbus Behçet, or Silk Road disease, is a rare immune-mediated systemic vasculitis. The more common symptoms include sores ... Read More
-
Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
... Summary According to the recently published report 'Superoxide Dismutase [Cu-Zn] - Drugs In Development, 2022'; Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) pipeline Target constitutes ... Read More
-
Asthma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... overview of the Asthma (Respiratory) pipeline landscape. Asthma is a chronic disease involving the airways in the lungs. These airways, or bronchial tubes, allow air to come in and out of the lungs. Symptoms include ... Read More
-
Critical Limb Ischemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... Development, 2022, provides an overview of the Critical Limb Ischemia (Cardiovascular) pipeline landscape. Critical limb ischemia (CLI) is the most severe form of peripheral arterial disease (PAD). It is caused by chronic inflammatory processes associated ... Read More
-
Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
... pipeline Target constitutes close to 10 molecules, which are developed by Companies. The latest report Growth Differentiation Factor 8 - Drugs In Development, 2022, outlays comprehensive information on the Growth/Differentiation Factor 8 (Myostatin or GDF8 ... Read More
-
Gastric Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... provides an overview of the Gastric Cancer (Oncology) pipeline landscape. Gastric cancer, also called stomach cancer, is a malignant tumor arising from the lining of the stomach. Signs and symptoms of gastric cancer include fatigue, ... Read More
-
Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
... Update Summary Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) pipeline Target constitutes close to 19 molecules. Out of which approximately 14 molecules are developed ... Read More
-
Cataract Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... overview of the Cataract (Ophthalmology) pipeline landscape. Cataract is a clouding of the normally clear lens of eye that affects vision. Symptoms include clouded, blurred or dim vision, increasing difficulty with vision at night, fading ... Read More
-
Allergic Conjunctivitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... provides an overview of the Allergic Conjunctivitis (Ophthalmology) pipeline landscape. Allergic conjunctivitis occurs when the clear layer of tissue lining the eyelids and covering the white of the eye (conjunctiva) become swollen or inflamed due ... Read More
-
Organophosphate and Carbamate Poisoning Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... Drugs In Development, 2022, provides an overview of the Organophosphate and Carbamate Poisoning (Toxicology) pipeline landscape. Organophosphates and carbamates are common insecticides that inhibit cholinesterase activity, causing acute muscarinic manifestations (salivation, lacrimation, urination, diarrhea, emesis, ... Read More
-
Adrenocortical Carcinoma (Adrenal Cortex Cancer) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... Cancer) - Drugs In Development, 2022, provides an overview of the Adrenocortical Carcinoma (Adrenal Cortex Cancer) (Oncology) pipeline landscape. Adrenal cortex cancer (ACC) is a rare disease. It is caused by a cancerous growth in ... Read More
Research Assistance
